Specifically, NICE’s recommends Keytruda as an option with chemotherapy for neoadjuvant, and alone as adjuvant treatment after surgery for patients with early triple-negative or locally advanced breast cancer.
The decision marks the first time patients in England with triple-negative breast cancer (TNBC) will be able to access immunotherapy at an earlier stage in their treatment journey, reducing the risk of their cancer returning and resulting in more positive treatment outcomes.
The recommendation was based on positive results from the KEYNOTE-522 trial in 1,174 patients with newly diagnosed, previously untreated and non-metastatic TNBC…
